Advertisement

Topics

IFNα-Kinoid - Biotech, Pharma and Life Science Channel

01:31 EST 24th January 2019 | BioPortfolio

Lupus : A major unmet medical need

Lupus is a chronic and severe autoimmune disease in which the immune system produces antibodies to cells within the body leading to widespread inflammation and tissue damage. It may affect multiple organ systems, including the skin, the joints, the heart, the lungs and the kidneys. It can result in arthritis, kidney failure, cardio-vascular and pulmonary problems, nervous system disorders, inflammation of the circulatory system and hematologic abnormalities. Lupus is a life-threatening disease, with mortality most frequently a result of secondary effects of the disease, most commonly glomerular nephritis leading to kidney failure. Lupus disease may first occur at any age, though peak diagnosis is between the ages of 15 and 40. It is far more common in women than men: approximately 90% of cases are diagnosed in women. Prevalence estimates for the disease vary widely, and range as high as 1.5 million in North America (the Lupus Foundation of America) and 5 million worldwide.

There is currently no targeted therapy for lupus: rather the treatment strategy is to control symptoms and prevent disease flares. This strategy relies on the use of corticosteroids and immunosuppressants, which have significant tolerability and toxicity issues in a chronic use setting. Some biologics are also used off-label, but their efficacy appears modest.

Source: http://www.neovacs.fr/en/products/IFNa-Kinoide

News Articles [9 Associated News Articles listed on BioPortfolio]

NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT ...

Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs and Centurion Pharma continue their collaboration in Lupusbased on the results of the Phase IIb trial with IFNalpha Kinoid P...

KOL Perspectives: MidtoLate Stage Pipeline Therapies in Lupus [Report Updated: 01022018] Prices from USD $2125

KOL Perspectives: MidtoLate Stage Pipeline Therapies in LupusSummaryThis KOL Insight briefing focuses on opinions of mid to latestage pipeline therapies in lupus.The briefing includes analysis of KOL ...

Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/IL-13 for the treatment of allergies

                            PRESS RELEASE · PRESS RELEASE · PRESS RELEASE                  Neovacs announces the patent filing in Europe and in the U...

Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma ...

Neovacs SA ALNEV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryNeovacs SA Neovacs is a biotechnology company that develops various therapeutic vaccines for the treatment of autoimmune disorders, inflammatory diseases and cancers. The company offers TNF kin...

KOL Perspectives: MidtoLate Stage Pipeline Therapies in Lupus [Report Updated: 01022018] Prices from USD $2500

KOL Perspectives: MidtoLate Stage Pipeline Therapies in LupusSummaryThis KOL Insight briefing focuses on opinions of mid to latestage pipeline therapies in lupus.The briefing includes analysis of KOL ...

NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO TREAT LUPUS IN CHINA

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE  NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO...

Neovacs SA ALNEV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23042018] Prices from USD $250

SummaryNeovacs SA Neovacs is a biotechnology company which develops various therapeutic vaccines for autoimmune disorders, inflammatory diseases and cancers. The company offers TNF kinoid and IFNa kin...

Companies [0 Results]

None

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

Study of IFN-K in Dermatomyositis

This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα antibodies (immune response) in adult subjects with dermatomyositis

Study of IFN-K in Systemic Lupus Erythematosus

The safety and immunogenicity of the IFN-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with SLE. Preliminary results were promising. The principal a...

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa 2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-...

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer

Influenza vaccination reduces the morbidity and mortality associated with influenza infection in at risk groups including the elderly and individuals with an impaired immune response, but...

Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists and ADA

The objective of this trial is to demonstrate that active immunization with anti-TNFα kinoid (TNF-K) is able to induce polyclonal anti-TNFα antibodies in RA patients who were previously ...

Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be an attr...

Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease

Evaluation of the safety and the immune response induced by active immunization through a TNFa kinoid in patients with Crohn's disease.

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.

Pegylated interferon-α (peg-IFNa) treatment induces molecular responses (MR) in patients with myeloproliferative neoplasms (MPNs), including partial MR (PMR) in 30-40% of patients. Here, we compared ...

Knock-out IFNL4 gene variant is associated with protection from sexually transmitted HIV-1 infection.

The IFNL4 knock-out allele (rs368234815-TT) is associated with spontaneous and IFNA-dependent cure of HCV. The role of this polymorphism in susceptibility to HIV-1 infection is controversial. This stu...

Medical and Biotech [MESH] Definitions

None available.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...